

LETTER OF ANNOUNCEMENT
The European Medicines Verification System's 4th year anniversary

9th February 2023

On this day, EMVO is happy to mark the European Medicines Verification ("EMVS") System 4th Anniversary.


Throughout these 4 years, EMVO and the NMVOs together with their numerous partners, have managed to implement an ambitious system that is effectively keeping the medical supply chain in Europe safe from falsified medicines.

The EMVS is a world-first for its stakeholder model, its scale and its use of new technologies. It is impressive to see that the system interconnects 2.800 pharmaceutical companies, 4.000 wholesale distribution authorisation holders, 110.000 pharmacies, 6.000 hospital pharmacies and 800 dispensing doctors in 29 countries. Please refer to the infographic to find out more facts and figures of the EMVS.

On this important day, EMVO's General Manager Andreas Walter shares some thoughts with the EMVS Community:

"Looking back at the 4 years since the "go-live" of the EMVS, I am extremely proud to see how much we have managed to achieve in such a short time. We were set with an ambitious project which most would have thought to be impossible to implement, and yet, the system has been fully operational since the 9th February 2019, and has been securing the medical supply chain and ultimately protecting the European citizens.

Just in the past year we have achieved and implemented some of our biggest milestones, such as the successful completion of the European Alerts Management System (EAMS) pilot. We are now pleased to confirm that the system is technically ready





and officially “live” from today – 9th February 2023! With the production launch of the EAMS, EMVO and its European partners aim towards achieving a full harmonisation of alerts handling across Europe, while providing a cost effective and time efficient alert management tool. This is a long and exciting journey during which we hope as many interested OBPs and NMVOs connect and take advantage of the functionalities the system offers.

We also successfully deployed numerous EU Hub Release, last one being Release 1.12. The continuous EU Hub Releases ensure our users that we are always working towards further improving and securing the system to meet the highest possible standards when it comes to IT security and readiness.

Throughout 2023, EMVO will continue its dedicated work in achieving the shared mission – patient safety. Therefore, I take this opportunity to encourage the active involvement and perseverance of the National Competent Authorities (NCAs) and the European Commission in addressing the ongoing challenges at European and national level which encompass the end of the stabilization period, end-user connection, alert harmonization and the timely connection of Greece and Italy to the EMVS.

I am proud of the work and the achievements of the past 4 years and hope to further promote a seamless and collaborative work environment within the EMVS community. All of these achievements would not have been possible without the strong collaboration of our partners, including our Stakeholders¹, the National Medicines Verification Organisations (NMVOs), the MAHs/On-Boarding Partners (OBPs), the authorities and end-users (pharmacies, hospitals, wholesaler), which I sincerely thank for their amiable and never-ending support.”

Tina Hou Marer, the upcoming Chair of the EU Change Control Board, also shares with us some of her thoughts on the EMVS.

“By February 9th, 2023, we celebrate the 4th Anniversary of the EMVS and FMD. We have come a long way since the early start 4 years ago. We have succeeded in operating, maintaining and further developing a robust system. We have only succeeded doing this through close collaboration, and the implementation of cross-cutting solutions, thus ensuring system interoperability. The collaboration can be seen in many instances. I would like to emphasize the good cooperation in the customer groups, where agreement on changes that benefit the majority is achieved. Well-functioning customer groups are the foundation for a successful EU Change Control Board (EU CCB).

The EU CCB was established in April 2020. The tasks of the EU CCB was to become an efficient driver for system related decisions and to have a clear mandate in order to stabilize the system performance. In order to attain this goal, the EU CCB must have a clear decision making process, strong management and firm control over the documentation. The EU CCB must build confidence for the governance model and process and ensure transparency between all stakeholders.

¹ EMVO Stakeholders: Affordable Medicines Europe, European Association of Hospital Pharmacists, European Federation of Pharmaceutical Industries and Associations, European Healthcare Distribution Association, European Hospital and Healthcare Federation, Medicines for Europe and Pharmaceutical Group of the European Union.



As the soon to be Chair of the EU CCB, I am very happy to say, that this is exactly what we have achieved, and having more than 400 changes approved since April 2020, speaks for itself. We have established processes, which provide full transparency to all stakeholders. Roles and responsibilities are clearly defined, and we have not once used the casting vote, but have always looked for ways to handle the obstacles which inevitably appear. Therefore I am confident that this excellent collaboration will continue to evolve in the coming year. I see a strong will to continue to improve the EU CCB processes and strengthen cooperation.

I would like to congratulate everyone on the 4th anniversary. We can be very proud of what we have achieved together through cooperation and a strong will to succeed. Happy birthday EMVS.”

To find out more about EMVO, the EMVS and our ongoing ambitious mission, please visit our [website](#) or [LinkedIn page](#).

Tel. Helpdesk: **+32 (0)2 657 00 08**

E-Mail: helpdesk@emvo-medicines.eu

EMVO Team

European Medicines Verification Organisation

www.emvo-medicines.eu

helpdesk@emvo-medicines.eu

EMVO © 2023. All rights reserved.

EMVO_10A_0275